MCET (MultiCell Technologies) Total Liabilities: $1.92 Mil (As of Aug. 2015)


What is MultiCell Technologies Total Liabilities?

MultiCell Technologies MCET -90.00% Total Liabilities is $1.92 Mil as of Aug. 2015.

MultiCell Technologies's Total Liabilities for the quarter that ended in Aug. 2015 was $1.92 Mil.

MultiCell Technologies's quarterly Total Liabilities increased from Feb. 2015 ($1.78 Mil) to May. 2015 ($1.87 Mil) and increased from May. 2015 ($1.87 Mil) to Aug. 2015 ($1.92 Mil).

MultiCell Technologies's annual Total Liabilities declined from Nov. 2012 ($1.83 Mil) to Nov. 2013 ($1.75 Mil) and declined from Nov. 2013 ($1.75 Mil) to Nov. 2014 ($1.64 Mil).

MultiCell Technologies Total Liabilities Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Total Liabilities Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.69 2.47 1.83 1.75 1.64

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 1.64 1.78 1.87 1.92

MultiCell Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MultiCell Technologies's Total Liabilities for the fiscal year that ended in Nov. 2014 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.181+(0.036+0.026
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.4+0+0)
=1.64

Total Liabilities=Total Assets (A: Nov. 2014 )-Total Equity (A: Nov. 2014 )
=0.126--1.517
=1.64

MultiCell Technologies's Total Liabilities for the quarter that ended in Aug. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.537+(0+0.017
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.363+0+0)
=1.92

Total Liabilities=Total Assets (Q: Aug. 2015 )-Total Equity (Q: Aug. 2015 )
=0.296--1.621
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.92 Mil mean?
MultiCell Technologies (MCET) has a Total Liabilities of $1.92 Mil as of Aug. 2015. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MultiCell Technologies and its competitors.
Is MultiCell Technologies' Total Liabilities too high?
MultiCell Technologies' current Total Liabilities is $1.92 Mil.
How does MultiCell Technologies' Total Liabilities compare to ERGO and OPLI?
MultiCell Technologies' Total Liabilities of $1.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MultiCell Technologies and its competitors. MultiCell Technologies's current Total Liabilities is $1.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Total Liabilities of $1.92 Mil. The current Total Liabilities is $1.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Total Liabilities is $1.92 Mil as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.